Maggie is a lead editor for The American Journal of Managed Care® (AJMC®), AJMC.com, and Evidence-Based Oncology, for which she produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and she has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Because persons living with HIV (PLWH) are now living longer, issues beyond their positive serostatus are having an adverse impact on their quality of life (QOL), such as obesity; recent research findings note these should be a consideration when choosing how to manage HIV.
Peter Hotez, MD, PhD, FASTMH, professor of pediatrics and molecular virology and dean, National School of Tropical Medicine, Baylor College of Medicine, and codirector, Texas Children’s Hospital Center for Vaccine Development, addresses the approval of the Pfizer/BioNTech COVID-19 vaccine for children aged 5 to 11 and emphasized its benefits far outweigh the rare possibility of myocarditis.
Polycystic ovary syndrome (PCOS) is one of the most common reproductive endocrine and metabolic diseases in women of childbearing age, but data that compare outcomes between obese and nonobese patients are scarce—something this study sought to remedy.
For 3 categories of evaluation, elevated cardiac troponin I levels most influenced the development of myocardial injury among persons at higher lifetime weight totals.
Amanda Ely, CEO, introduces us to The Children's HIV Association (CHIVA) of the United Kingdom and Ireland and details how the experiences of young persons living with HIV differ from those who acquire the virus as adults.
This new study from Serbia compared outcomes on oral glucose tolerance tests between women who are pregnant and those who have polycystic ovary syndrome (PCOS).
Jason Myers, PhD, CEO of the New Zealand AIDS Foundation, delves into how services related to HIV and AIDS in New Zealand—treatment and prevention, and now holistic services—have been spurred to expansion in recent years.
A new study from Turkey shows, among other results, that delayed initiation of treatment with growth hormone among pediatric patients may lead to minimal height improvements despite adherence to the therapy.
With sleep apnea and abnormal sleep patterns typifying Prader-Willi syndrome, researchers from Sweden and Denmark theorized that treatment with growth hormone may improve both for individuals affected by the rare neurodevelopmental disease.
New data presented at IDWeek 2021 show lack of pre-exposure prophylaxis (PrEP) uptake among groups at high risk of HIV infection.
University of Birmingham researchers point to potential benefits via reduced unbound active androgens, low levels of which increase the body’s response to insulin and decrease the likelihood of hirsutism in women with polycystic ovary syndrome (PCOS) at risk of developing type 2 diabetes (T2D).
The American Journal of Managed Care® recently spoke with Nicoleta Dascalu, founding member and advocacy manager of Asociaţia Română Anti-SIDA (ARAS; Romanian Association Against AIDS) to learn more about ARAS, which was founded in April of 1992, just 3 years after the fall of communism in the country.
Focused educational improvements are needed for women of reproductive age and those who are pregnant regarding vertical transmission of HIV and its prevention.
New data on treatment for newly diagnosed pulmonary arterial hypertension (PAH) show initial treatment for the progressive disease that includes macitentan has potential to reduce risk of disease progression.
Research presented at EHA2021 shows that the JAK 1/2 inhibitor ruxolitinib produced cost-effective benefits per quality-adjusted life-year and increased the overall survival rate for patients with myelofibrosis.
Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health and director of the Center for Health, Identity, Behavior and Prevention Studies, discusses how the HIV/AIDS crisis and the ongoing COVID-19 pandemic parallel one another and how both are teaching opportunities.
Christine Ko, MD, professor of dermatology and pathology at Yale University, who specializes in transplant dermatology, explains the considerations involved with skin cancer–related treatment decisions among patients who’ve undergone a solid-organ or other type of organ transplant.
Dawn Averitt, founder of The Well Project and Women's Research Initiative on HIV/AIDS, has been living with HIV for 33 years.
This new analysis of 5-year data on a novel gene therapy from PTC Therapeutics shows both cognitive and motor function improvement in children with aromatic L-amino acid decarboxylase (AADC) deficiency, a rare central nervous system disorder.
This analysis of Veterans Aging Cohort Study participants highlighted 2 factors that may predispose persons living with HIV to a higher risk of sudden cardiac death.
This new study of primary care patients in the United Kingdom investigated the impact of Headspace, a mindfulness-focused app, on asthma-related quality of life (QOL).
Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas, explains the process of Mohs surgery for removing skin cancers and preserving healthy surrounding tissue.
A new report from the CDC details how testing for HIV and care for the disease among at-risk populations were affected by the COVID-19 pandemic and proposes that self-testing may be a workable solution.
This follow-up study of patients first analyzed 10 years ago sought to determine if health-related quality of life (HRQOL) was still a reliable predictor of Parkinson disease severity, especially at it relates to Hoehn-Yahr stage increase.
This London-based charity intervenes in the short term when its clients come up against roadblocks that prevent ready access to good levels of nutrition, whether that crisis is nutritional, physical/mental health, housing, or financial related.
With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.
A new analysis of 2014-2018 data among all states plus Washington, DC, for those who have either indications for preexposure prophylaxis (PrEP) or current prescriptions for the preventive treatment, shows a widening gap in PrEP uptake, with states considered early adopters pulling ahead of those considered late adopters.
Entresto (sacubitril/valsartan) was first approved for use in heart failure with reduced ejection fraction (HFrEF) in 2015.
Differentiated service delivery models can be employed to incorporate other chronic disease needs for patients with HIV, emphasized Helen Bygrave, MD, Médecins Sans Frontières (Doctors Without Borders).
